Wayne Batchelor

Background

About Wayne Batchelor

Dr. Wayne Batchelor currently serves as the Director or Interventional Cardiology, Director of Interventional Cardiology Research, Innovation and Education and Associate Director of the Inova Heart and Vascular Institute in Fairfax, VA and Adjunct Professor of Medicine at Duke University. Dr. Batchelor’s clinical and research interests span a broad range of complex percutaneous coronary and structural heart interventions (PCI), including transcatheter mitral valve repair/replacement, transcatheter aortic valve replacement (TAVR), percutaneous left atrial appendage closure, ASD/PFO closure, cardiogenic shock and high risk PCI including chronic coronary artery occlusion a (CTO). He has presented hundreds of invited lectures, published over 200 peer-reviewed original abstracts/manuscripts, multiple book chapters and has participated in over 175 clinical trials, including serving as Principal Investigator in over 50 and on several National/International Clinical Trial Steering Committees. He recently served as the National Co-Principal Investigator of the PLATINUM DIVERSITY study, the first and only study to prospectively evaluate clinical outcomes in minorities and women after coronary stent procedures across 52 U.S. sites. He is currently National PI of the ALERT study, a multi-center prospective randomized trial that will evaluate the efficacy of cardiac intelligence software in identifying under treated patients with aortic stenosis who are potential candidates for valve replacement. Dr. Batchelor holds numerous leadership positions within several national and international cardiology organizations, including Co-Chair of the NCDR STS/ACC TVT Registry Steering Committee, Chair of the American College of Cardiology's (ACC) Interventional Sectional Leadership Council, Program Committee Member for the 2023 ACC/World Congress of Cardiology Scientific Sessions, Member of the Scientific Program Committee of the Transcatheter Cardiovascular Therapeutics (TCT) Meeting, AHA Committee for the 2023 Scientific Sessions Program, SCAI Vascular Disease Council, and the SCAI Diversity, Equity and Inclusion Taskforce. He also serves on the Editorial Board of JSCAI and Cardiovascular Revascularization Medicine (CRM) and as a special government employee/consultant to the U.S. Food and Drug Administration (FDA) within the Cardiovascular Devices Branch. Dr. Batchelor is currently pursuing an Executive MBA from the NYU Stern School of Business (DC'24 cohort).